VG-102

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameVG-102
Drug Alias Nameanti-CD55 antibody (Viragen/Cancer Research/University of Nottingham)791Tgp72GBP-102VG-102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement decay-accelerating factor modulators
TargetsComplement decay-accelerating factor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Nottingham
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViragenIovance Biotherapeutics IncUniversity Of Nottingham +[4] 
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A